BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 94 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $1,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q1 2022 | $1,000 | -50.0% | 500 | 0.0% | 0.00% | – |
| Q4 2021 | $2,000 | +100.0% | 500 | 0.0% | 0.00% | – |
| Q3 2021 | $1,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q2 2021 | $1,000 | 0.0% | 500 | 0.0% | 0.00% | – |
| Q1 2021 | $1,000 | -50.0% | 500 | 0.0% | 0.00% | – |
| Q4 2020 | $2,000 | -97.0% | 500 | -87.5% | 0.00% | – |
| Q3 2020 | $67,000 | +52.3% | 4,000 | 0.0% | 0.00% | – |
| Q2 2020 | $44,000 | +144.4% | 4,000 | 0.0% | 0.00% | – |
| Q1 2020 | $18,000 | +5.9% | 4,000 | 0.0% | 0.00% | – |
| Q4 2019 | $17,000 | +13.3% | 4,000 | 0.0% | 0.00% | – |
| Q3 2019 | $15,000 | +15.4% | 4,000 | +14.3% | 0.00% | – |
| Q2 2019 | $13,000 | -13.3% | 3,500 | 0.0% | 0.00% | – |
| Q1 2019 | $15,000 | +25.0% | 3,500 | 0.0% | 0.00% | – |
| Q4 2018 | $12,000 | -7.7% | 3,500 | 0.0% | 0.00% | – |
| Q3 2018 | $13,000 | 0.0% | 3,500 | 0.0% | 0.00% | – |
| Q2 2018 | $13,000 | +18.2% | 3,500 | 0.0% | 0.00% | – |
| Q1 2018 | $11,000 | -15.4% | 3,500 | 0.0% | 0.00% | – |
| Q4 2017 | $13,000 | -7.1% | 3,500 | 0.0% | 0.00% | – |
| Q3 2017 | $14,000 | – | 3,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Weaver Consulting Group | 130,000 | $437,000 | 0.21% |
| Ikarian Capital, LLC | 304,161 | $1,022,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 265,000 | $890,000 | 0.12% |
| S.C. Financial Services, Inc. | 15,285 | $51,000 | 0.06% |
| JMAC ENTERPRISES LLC | 45,430 | $153,000 | 0.04% |
| CFO4Life Group, LLC | 12,000 | $40,000 | 0.01% |
| OSAIC HOLDINGS, INC. | 10,839 | $1,329,000 | 0.00% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $10,000 | 0.00% |
| BOOTHBAY FUND MANAGEMENT, LLC | 29,186 | $98,000 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 190,403 | $640,000 | 0.00% |